Oncology Programs at the FDA
Time spent developing novel cancer therapies is frequently measured in decisions as much as duration–each decision may speed a promising therapy to patients or lead to delay. For sponsors, understanding the full scope of programs offered by the FDA to speed up the approval of cancer treatments is critical.
To learn more about key decision points at each stage of development, please see our recent blogs and webinar which provide a review of these programs: how to apply for them, how to apply them to drug development challenges, and their consequences for the future of oncology approvals.
Register for our webinar: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology
Suggested For You
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval

regulatory intelligence
August 9th, 2024
FDA Updates 2024 Language Access Plan

regulatory intelligence
July 26th, 2024
Key Decision Points for Recent Oncology Approvals

regulatory intelligence
August 3rd, 2024
EMA Launches New Pilot Program for Orphan Medical Devices

regulatory intelligence
July 24th, 2024
Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
regulatory intelligence
July 8th, 2024
FDA Works to Reduce the Spread of Misinformation
regulatory intelligence
June 26th, 2024
New Details on Diversity Action Plans Provided by the US FDA
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

perspectives
July 16th, 2024
Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives
July 9th, 2024
Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives
July 2nd, 2024
Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology